The U.S. Defense Department has awarded $3.5 million to a Cambridge, Mass., biotech that says it has figured out a way to make blood platelets from stem cells, a technology the military believes could be useful in treating battlefield and civilian casualties.
Platelet BioGenesis, which was founded in 2014, said Wednesday that the grant will help the startup develop a bioreactor that is key to the production of platelets, a critical component of blood that promotes clotting.
Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!
GET STARTEDWhat is it?
STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.
What's included?
- Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
- Subscriber-only networking events and panel discussions across the country
- Monthly subscriber-only live chats with our reporters and experts in the field
- Discounted tickets to industry events and early-bird access to industry reports
I,m glad to read such a detailed description of your work. I,m sure you will make a great contribution to medical science.